New research presented at SLEEP 2025 links increased auditory cortex excitability with poor sleep efficiency in children—especially those with autism spectrum disorder—offering insight into sensory-driven sleep disturbances.
May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.
A new multinational study found that removing the full extent of noncontrast-enhanced tumor seen on MRI scans led to significantly longer survival in patients with IDH wild-type glioblastoma.